Sugi Predict

Sugi Predict / Compounds / SCHEMBL137029

SCHEMBL137029

SCHEMBL137029

COC(=O)Cc1cccc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIPG Q9Y5X9 4/20 0.53
▸ LPL P06858 3/20 0.53
▸ SLC7A5 Q01650 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ HSP90AB1 P08238 1/20 0.41
▸ HIF1A Q16665 3/20 0.40
▸ ROCK1 Q13464 1/20 0.40
▸ DGAT1 O75907 1/20 0.39
▸ HPGD P15428 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ NPC1 O15118 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ F11 P03951 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1238039 0.86 LIPG (0.54) LIPGLPLHIF1AROCK1NPC1
SCHEMBL10733 0.86 LIPG (0.58) LIPGLPLHIF1ADGAT1CYP4F2
SCHEMBL14366710 0.85 LIPG (0.50) LIPGLPLSLC7A5HIF1AROCK1
SCHEMBL108008 0.84 LIPG (0.57) LIPGLPLGAAHIF1AROCK1
SCHEMBL13967586 0.84 LIPG (0.57) LIPGLPLHIF1AROCK1F11
SCHEMBL13336438 0.83 LIPG (0.53) LIPGLPLHIF1AROCK1CYP4F2
SCHEMBL901566 0.83 LIPG (0.56) LIPGLPLHIF1AROCK1F11
SCHEMBL30858793 0.83 LIPG (0.56) LIPGLPLHIF1AROCK1F11
SCHEMBL16396798 0.83 CFD (0.43) LIPGLPLROCK1DGAT1NPC1
SCHEMBL481948 0.82 LIPG (0.53) LIPGLPLALDH1A1GAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
EP-2970176-B1 MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO CORTEVA AGRISCIENCE LLC (US) 2023-10-25 — — EP disclosed
US-20230079863-A1 KHK INHIBITORS GILEAD SCIENCES, INC. 2023-03-16 — — US disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 — — WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 — — WO disclosed
US-6919353-B2 Substituted 8-arylquinolune PDE4 inhibitors MERCK FROSST CANADA & CO. (CA) 2005-07-19 — — US disclosed
EP-1404330-B1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA INC (CA) 2005-06-01 — — EP disclosed
US-20050080111-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2005-04-14 — — US disclosed
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-10-28 — — US disclosed
US-20040162314-A1 Substituted 8-arylquinolune pde4 inhibitors MERCK FROSST CANADA LTD. (CA) 2004-08-19 — — US disclosed
EP-1404330-A1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS Merck Frosst Canada & Co. (CA) 2004-04-07 — — EP disclosed
EP-1394147-A1 CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME Eisai Co., Ltd. (JP) 2004-03-03 — — EP disclosed
WO-2003002118-A1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162314-A1 Substituted 8-arylquinolune pde4 inhibitors PDE12, PDE4A, PDE4B LIPG 3904/4885LPL 2953/4885SLC7A5 4535/4885
US-20050080111-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 LIPG 603/4885LPL 299/4885SLC7A5 3295/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS LIPG 1148/4885LPL 2115/4885SLC7A5 1341/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 LIPG 249/4885LPL 178/4885SLC7A5 1530/4885
US-20230079863-A1 KHK INHIBITORS KHK, KHDRBS1, NADK LIPG 2261/4885LPL 3327/4885SLC7A5 1899/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK LIPG 2261/4885LPL 3327/4885SLC7A5 1899/4885
US-20040214888-A1 Carboxylic acid derivative and medicine comprising salt or ester of the same GPR119, NR3C1, INSR LIPG 1688/4885LPL 1196/4885SLC7A5 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.